Health
Lipid metabolism transcriptomics of murine microglia in Alzheimer’s disease and neuroinflammation
Gallardo, G. & Holtzman, D. M. Amyloid-beta and Tau at the crossroads of Alzheimer’s disease. Adv. Exp. Med. Biol. 1184, 187–203. https://doi.org/10.1007/978-981-32-9358-8_16 (2019).
Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here? Nat. Rev. Neurol. 17, 157–172. https://doi.org/10.1038/s41582-020-00435-y (2021).
Dhillon, S. Aducanumab: First approval. Drugs 81, 1437–1443. https://doi.org/10.1007/s40265-021-01569-z (2021).
Hoy, S. M. Lecanemab: First approval. Drugs 83, 359–365. https://doi.org/10.1007/s40265-023-01851-2 (2023).
Reardon, S. FDA approves Alzheimer’s drug lecanemab amid safety concerns. Nature 613, 227–228. https://doi.org/10.1038/d41586-023-00030-3 (2023).
Alexander, G. C., Emerson, S. & Kesselheim, A. S. Evaluation of aducanumab for Alzheimer disease: Scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA 325, 1717–1718. https://doi.org/10.1001/jama.2021.3854 (2021).
Anderson, T. S., Ayanian, J. Z., Souza, J. & Landon, B. E. Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for Alzheimer disease compared with medicare beneficiaries with Alzheimer disease and mild cognitive impairment. JAMA 326, 1627–1629. https://doi.org/10.1001/jama.2021.15286 (2021).
Razay, G., Vreugdenhil, A. & Wilcock, G. The metabolic syndrome and Alzheimer disease. Arch. Neurol. 64, 93–96. https://doi.org/10.1001/archneur.64.1.93 (2007).
Chausse, B., Kakimoto, P. A. & Kann, O. Microglia and lipids: How metabolism controls brain innate immunity. Semin. Cell Dev. Biol. 112, 137–144. https://doi.org/10.1016/j.semcdb.2020.08.001 (2021).
Loving, B. A. & Bruce, K. D. Lipid and lipoprotein metabolism in microglia. Front. Physiol. 11, 393. https://doi.org/10.3389/fphys.2020.00393 (2020).
O’Brien, J. S. & Sampson, E. L. Lipid composition of the normal human brain: Gray matter, white matter, and myelin. J. Lipid Res. 6, 537–544 (1965).
Montanini, I., Gatti, C., Woelk, H. & Porcellati, S. The influence of polyunsaturated phosphatidylcholine on brain lipid synthesis during aging. Farmaco Sci. 38, 376–382 (1983).
Sastry, P. S. Lipids of nervous tissue: Composition and metabolism. Prog. Lipid Res. 24, 69–176. https://doi.org/10.1016/0163-7827(85)90011-6 (1985).
Bjorkhem, I. & Meaney, S. Brain cholesterol: Long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24, 806–815. https://doi.org/10.1161/01.ATV.0000120374.59826.1b (2004).
Puglielli, L., Tanzi, R. E. & Kovacs, D. M. Alzheimer’s disease: The cholesterol connection. Nat. Neurosci. 6, 345–351. https://doi.org/10.1038/nn0403-345 (2003).
Roses, A. D. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu. Rev. Med. 47, 387–400. https://doi.org/10.1146/annurev.med.47.1.387 (1996).
Dallongeville, J., Lussier-Cacan, S. & Davignon, J. Modulation of plasma triglyceride levels by apoE phenotype: A meta-analysis. J. Lipid Res. 33, 447–454 (1992).
Carvalho-Wells, A. L., Jackson, K. G., Lockyer, S., Lovegrove, J. A. & Minihane, A. M. APOE genotype influences triglyceride and C-reactive protein responses to altered dietary fat intake in UK adults. Am. J. Clin. Nutr. 96, 1447–1453. https://doi.org/10.3945/ajcn.112.043240 (2012).
Dunk, M. M., Driscoll, I., Alzheimer’s Disease Neuroimaging Initiative. Total cholesterol and APOE-related risk for Alzheimer’s disease in the Alzheimer’s disease neuroimaging initiative. J. Alzheimers Dis. 85, 1519–1528. https://doi.org/10.3233/JAD-215091 (2022).
Zhang, X. et al. Midlife lipid and glucose levels are associated with Alzheimer’s disease. Alzheimers Dement. https://doi.org/10.1002/alz.12641 (2022).
Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160, 1061–1071. https://doi.org/10.1016/j.cell.2015.01.049 (2015).
Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. J. Neurosci. 26, 10129–10140. https://doi.org/10.1523/JNEUROSCI.1202-06.2006 (2006).
Cotto, K. C. et al. DGIdb 3.0: A redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 46, D1068–D1073. https://doi.org/10.1093/nar/gkx1143 (2018).
Freshour, S. L. et al. Integration of the drug–gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. 49, D1144–D1151. https://doi.org/10.1093/nar/gkaa1084 (2021).
Skoog, I. et al. 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141–1145. https://doi.org/10.1016/s0140-6736(96)90608-x (1996).
Simons, M. et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52, 346–350. https://doi.org/10.1002/ana.10292 (2002).
Green, R. C. et al. Statin use and the risk of Alzheimer’s disease: The MIRAGE study. Alzheimers Dement. 2, 96–103. https://doi.org/10.1016/j.jalz.2006.02.003 (2006).
Geifman, N., Brinton, R. D., Kennedy, R. E., Schneider, L. S. & Butte, A. J. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. Alzheimers Res. Ther. 9, 10. https://doi.org/10.1186/s13195-017-0237-y (2017).
Husain, I. et al. Rosuvastatin ameliorates cognitive impairment in rats fed with high-salt and cholesterol diet via inhibiting acetylcholinesterase activity and amyloid beta peptide aggregation. Hum. Exp. Toxicol. 37, 399–411. https://doi.org/10.1177/0960327117705431 (2018).
Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360, 7–22. https://doi.org/10.1016/S0140-6736(02)09327-3 (2002).
Appleton, J. P., Scutt, P., Sprigg, N. & Bath, P. M. Hypercholesterolaemia and vascular dementia. Clin. Sci. 131, 1561–1578. https://doi.org/10.1042/CS20160382 (2017).
McGuinness, B., Craig, D., Bullock, R. & Passmore, P. Statins for the prevention of dementia. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD003160.pub3 (2016).
Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290. https://doi.org/10.1016/j.cell.2017.05.018 (2017).
Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566–581. https://doi.org/10.1016/j.immuni.2017.08.008 (2017).
Rustam, Y. H. & Reid, G. E. Analytical challenges and recent advances in mass spectrometry based lipidomics. Anal. Chem. 90, 374–397. https://doi.org/10.1021/acs.analchem.7b04836 (2018).
Daemen, S., van Zandvoort, M., Parekh, S. H. & Hesselink, M. K. C. Microscopy tools for the investigation of intracellular lipid storage and dynamics. Mol. Metab. 5, 153–163. https://doi.org/10.1016/j.molmet.2015.12.005 (2016).
Heppner, F. L., Ransohoff, R. M. & Becher, B. Immune attack: The role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16, 358–372. https://doi.org/10.1038/nrn3880 (2015).
Thirumangalakudi, L. et al. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J. Neurochem. 106, 475–485. https://doi.org/10.1111/j.1471-4159.2008.05415.x (2008).
Abuelezz, S. A. & Hendawy, N. HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis. Life Sci. 273, 119310. https://doi.org/10.1016/j.lfs.2021.119310 (2021).
Beutler, B. A. & Cerami, A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J. Immunol. 135, 3969–3971 (1985).
Doerrler, W., Feingold, K. R. & Grunfeld, C. Cytokines induce catabolic effects in cultured adipocytes by multiple mechanisms. Cytokine 6, 478–484. https://doi.org/10.1016/1043-4666(94)90074-4 (1994).
Heneka, M. T. et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 493, 674–678. https://doi.org/10.1038/nature11729 (2013).
Youm, Y. H. et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263–269. https://doi.org/10.1038/nm.3804 (2015).
Shippy, D. C., Wilhelm, C., Viharkumar, P. A., Raife, T. J. & Ulland, T. K. Beta-hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer’s disease pathology. J. Neuroinflamm. 17, 280. https://doi.org/10.1186/s12974-020-01948-5 (2020).
Cheret, C. et al. Neurotoxic activation of microglia is promoted by a nox1-dependent NADPH oxidase. J. Neurosci. 28, 12039–12051. https://doi.org/10.1523/JNEUROSCI.3568-08.2008 (2008).
Block, M. L., Zecca, L. & Hong, J. S. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57–69. https://doi.org/10.1038/nrn2038 (2007).
Li, Q. et al. Ascorbic acid 6-palmitate modulates microglia M1/M2 polarization in lipopolysaccharide-stimulated BV-2 cells via PERK/elF2alpha mediated endoplasmic reticulum stress. BMC Complement Med. Ther. 22, 302. https://doi.org/10.1186/s12906-022-03780-1 (2022).
Huang, S., Xing, Y. & Liu, Y. Emerging roles for the ER stress sensor IRE1alpha in metabolic regulation and disease. J. Biol. Chem. 294, 18726–18741. https://doi.org/10.1074/jbc.REV119.007036 (2019).
Wang, J. et al. The protective effects of phoenixin-14 against lipopolysaccharide-induced inflammation and inflammasome activation in astrocytes. Inflamm. Res. 69, 779–787. https://doi.org/10.1007/s00011-020-01355-9 (2020).
Liao, K. et al. Cocaine-mediated induction of microglial activation involves the ER stress-TLR2 axis. J. Neuroinflamm. 13, 33. https://doi.org/10.1186/s12974-016-0501-2 (2016).
Huang, D. & Jiang, Y. MKP1 reduces neuroinflammation via inhibiting endoplasmic reticulum stress and mitochondrial dysfunction. J. Cell Physiol. 235, 4316–4325. https://doi.org/10.1002/jcp.29308 (2020).
Stieber, A., Mourelatos, Z. & Gonatas, N. K. In Alzheimer’s disease the Golgi apparatus of a population of neurons without neurofibrillary tangles is fragmented and atrophic. Am. J. Pathol. 148, 415–426 (1996).
Long, H. Z. et al. The key roles of organelles and ferroptosis in Alzheimer’s disease. J. Neurosci. Res. 100, 1257–1280. https://doi.org/10.1002/jnr.25033 (2022).
Nordzieke, D. E. & Medrano-Fernandez, I. The plasma membrane: A platform for intra- and intercellular redox signaling. Antioxidants 7, 10168. https://doi.org/10.3390/antiox7110168 (2018).
Holtzman, D. M., Herz, J. & Bu, G. Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006312. https://doi.org/10.1101/cshperspect.a006312 (2012).
Ishibashi, S., Herz, J., Maeda, N., Goldstein, J. L. & Brown, M. S. The two-receptor model of lipoprotein clearance: Tests of the hypothesis in “knockout” mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc. Natl. Acad. Sci. U.S.A. 91, 4431–4435. https://doi.org/10.1073/pnas.91.10.4431 (1994).
Shi, Y. et al. Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron 109, 2413–2426. https://doi.org/10.1016/j.neuron.2021.05.034 (2021).
Bagyinszky, E., Giau, V. V. & An, S. A. Transcriptomics in Alzheimer’s disease: Aspects and challenges. Int. J. Mol. Sci. 21, 3517. https://doi.org/10.3390/ijms21103517 (2020).
Blair, J. A. et al. Individual case analysis of postmortem interval time on brain tissue preservation. PLoS ONE 11, e0151615. https://doi.org/10.1371/journal.pone.0151615 (2016).
Ulland, T. K. et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell 170, 649–663. https://doi.org/10.1016/j.cell.2017.07.023 (2017).
Sobue, A. et al. Microglial gene signature reveals loss of homeostatic microglia associated with neurodegeneration of Alzheimer’s disease. Acta Neuropathol. Commun. 9, 1. https://doi.org/10.1186/s40478-020-01099-x (2021).
Olah, M. et al. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer’s disease. Nat. Commun. 11, 6129. https://doi.org/10.1038/s41467-020-19737-2 (2020).
Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26, 131–142. https://doi.org/10.1038/s41591-019-0695-9 (2020).
Shippy, D. C., Watters, J. J. & Ulland, T. K. Transcriptional response of murine microglia in Alzheimer’s disease and inflammation. BMC Genom. 23, 183. https://doi.org/10.1186/s12864-022-08417-8 (2022).
Righi, M. et al. Monokine production by microglial cell clones. Eur. J. Immunol. 19, 1443–1448. https://doi.org/10.1002/eji.1830190815 (1989).
da Huang, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57. https://doi.org/10.1038/nprot.2008.211 (2009).
da Huang, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13. https://doi.org/10.1093/nar/gkn923 (2009).
Szklarczyk, D. et al. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide datasets. Nucleic Acids Res. 47, D607–D613. https://doi.org/10.1093/nar/gky1131 (2019).
Heberle, H., Meirelles, G. V., da Silva, F. R., Telles, G. P. & Minghim, R. InteractiVenn: A web-based tool for the analysis of sets through Venn diagrams. BMC Bioinform. 16, 169. https://doi.org/10.1186/s12859-015-0611-3 (2015).
Heng, T. S., Painter, M. W., Immunological Genome Project Consortium. The Immunological Genome Project: Networks of gene expression in immune cells. Nat. Immunol. 9, 1091–1094. https://doi.org/10.1038/ni1008-1091 (2008).
|
Sources 2/ https://www.nature.com/articles/s41598-023-41897-6 The mention sources can contact us to remove/changing this article |
What Are The Main Benefits Of Comparing Car Insurance Quotes Online
LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos
to request, modification Contact us at Here or [email protected]
 |
 |
 |
